2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation

Authors, Journal, Affiliations, Type, DOI

• Chair: Jose A. Joglar, MD; Vice-Chair: Mina K. Chung, MD
• Additional writing committee members from ACC, AHA, ACCP, HRS
• Journal: Circulation. 2024;149:e1–e156
• Type: Joint professional society clinical practice guideline
• DOI: 10.1161/CIR.0000000000001193

Overview

The 2023 ACC/AHA/ACCP/HRS Guideline provides the most comprehensive U.S. framework for AF management, replacing prior AF guidelines. Its major innovations include a new 4-stage AF classification (replacing duration-based categories), an explicit Lifestyle and Risk Factor Modification (LRFM) pillar, retention of sex as a CHA₂DS₂-VASc risk modifier (unlike the ESC 2024 CHA₂DS₂-VA), and upgraded catheter ablation recommendations. The guideline introduces device-detected AHRE management with duration-dependent anticoagulation thresholds and provides detailed guidance on early-onset AF genetics, athletes, HCM, and other special populations.

Keywords

Atrial fibrillation; AF staging; CHA₂DS₂-VASc; catheter ablation; pulmonary vein isolation; antiarrhythmic drugs; rate control; rhythm control; direct oral anticoagulants; left atrial appendage occlusion; lifestyle modification; early-onset AF; heart failure; shared decision-making

Key Takeaways

1. AF Classification and Staging (Section 3)

• New 4-stage classification replaces the prior duration-based schema:
  • Stage 1 — At Risk for AF: Risk factors present but no AF documented
  • Stage 2 — Pre-AF: Atrial structural/electrical changes (eg, frequent PACs, short AHRE runs, LA enlargement) without sustained AF
  • Stage 3 — AF: Documented AF (paroxysmal 3a, persistent 3b, long-standing persistent 3c, successful ablation 3d)
  • Stage 4 — Permanent AF: Accepted as permanent by patient and physician; no further rhythm control pursued
• Goal: earlier intervention to prevent progression

2. Lifestyle and Risk Factor Modification (LRFM) — Section 5

• Smoking cessation: Class I/B-NR — reduces AF incidence and recurrence
• Weight loss ≥10%: Class I/B-R — reduces AF burden; sustained weight loss most beneficial
• Physical activity: 210 min/week of moderate exercise reduces AF risk; vigorous endurance athletics (>45 MET-h/week) paradoxically increases AF risk
• Alcohol: Reduce/abstain; dose-dependent relationship with AF
• Caffeine: No restriction recommended (Class III: No Benefit for caffeine avoidance)
• Sleep apnea: Treatment reduces AF recurrence
• Diabetes control: Tight glycemic control reduces AF burden
• Hypertension: Aggressive treatment reduces AF incidence and recurrence

3. Stroke Prevention (Section 6)

• CHA₂DS₂-VASc score (sex retained as risk modifier — differs from ESC 2024 CHA₂DS₂-VA):
  • OAC recommended if ≥2 (Class I/A for men; Class I/B-NR for women)
  • OAC reasonable if =1 in men (Class IIa/B-NR); not routinely recommended if =0
  • Threshold is ≥2% per year stroke risk (Class I/A) or 1–2%/year (IIa/A)
• DOACs preferred over VKAs (Class I/A) except mechanical valves or moderate-severe mitral stenosis (warfarin Class I/B-R)
• HCM: CHA₂DS₂-VASc score should not be applied — equivalent to a score of 3; OAC indicated regardless of score
• pLAAO: Class IIa/B-NR for patients with contraindication to long-term OAC — upgraded from IIb (prior guidelines)
• Surgical LAA closure during cardiac surgery: Class I/A as adjunct to OAC (LAAOS III trial)

4. Device-Detected Subclinical AF / AHREs (Section 6.4)

• Duration-dependent anticoagulation thresholds:
  • AHRE ≥24 hours + CHA₂DS₂-VASc ≥2: OAC reasonable (Class IIa/B-NR — ARTESiA trial)
  • AHRE 5 min–24 hours + CHA₂DS₂-VASc ≥3: OAC may be considered (Class IIb/B-NR)
  • AHRE <5 minutes: OAC not recommended (Class III: No Benefit)

5. Rate Control (Section 7)

• Rate target: Resting HR <100–110 bpm in most patients without HF (RACE II trial; Class IIa/B-R)
• Acute rate control: Beta blockers or non-DHP CCBs first-line (Class I/B-R); diltiazem/verapamil contraindicated in LVEF <40%
• Long-term: Beta blockers or non-DHP CCBs preferred; digoxin reasonable adjunct in HF (target levels <1.2 ng/mL)
• Dronedarone: Contraindicated for permanent AF (PALLAS trial harm signal; Class III/B-R); also contraindicated in NYHA class III-IV HF

6. Rhythm Control — Goals (Section 8.1)

• Early rhythm control (<1 year from diagnosis): Reduces cardiovascular death, stroke, and HF hospitalization (EAST-AFNET 4 trial; Class IIa/B-R); benefit independent of symptom status
• Tachycardia-induced cardiomyopathy: Aggressive early rhythm control recommended when new HFrEF + AF (Class I/B-NR)

7. Catheter Ablation (Section 8.4)

• Class I/A: In patients with symptomatic AF in whom AADs are ineffective, contraindicated, or not preferred
• Class I/A (first-line): Selected younger patients with few comorbidities and paroxysmal AF seeking rhythm control — ablation is first-line (MANTRA-AF, EARLY-AF, STOP AF First trials)
• Class IIa/B-R: Other patients with paroxysmal or persistent AF as first-line rhythm control (broader group)
• Class IIb/B-NR: Asymptomatic/minimally symptomatic AF to reduce progression (younger, moderate-high AF burden or persistent AF)
• HFrEF (Class I/A): Catheter ablation beneficial if GDMT optimized and reasonable expectation of benefit (CASTLE-AF, CABANA HF substudy)
• HFpEF (Class IIa/B-NR): Catheter ablation can be useful to improve symptoms and QOL
• Ablation technique: PVI is the primary lesion set (Class I/A); additional targets beyond PVI have not reliably improved outcomes (Class IIb/B-R)
• Anticoagulation peri-ablation: Uninterrupted or minimally interrupted DOAC preferred (Class I/A); OAC continued ≥3 months post-ablation; long-term OAC dictated by stroke risk (CHA₂DS₂-VASc ≥2) regardless of ablation success
• Recurrence rate: 30–40% after first procedure; repeat ablation (Class I/B-NR) improves outcomes
• Complications: Overall ~5%; atrioesophageal fistula (rare, 0.2%, often fatal); tamponade (0.4–1.5%); stroke/TIA (<1%); PV stenosis (0.1–0.8%)

8. Antiarrhythmic Drugs (Section 8.3)

• HFrEF: Amiodarone (Class IIa/B-NR) or dofetilide (Class IIa/A) — most other AADs contraindicated
• No structural disease / no prior MI: Flecainide (Class IIa/A), propafenone (Class IIa/A), dronedarone (Class IIa/A)
• Flecainide/propafenone contraindicated in prior MI or significant structural heart disease (Class III/B-R — CAST trial)
• Inpatient initiation required for dofetilide (≥3 days) and sotalol (3-day monitoring)
• "Pill-in-the-pocket" (PITP): Flecainide or propafenone + AV nodal blocker — reasonable for infrequent paroxysmal AF after first supervised dose (Class IIa/A)

9. AF in Heart Failure (Section 9)

• AF-induced cardiomyopathy: AF is the most common cause — suspected when new HFrEF + AF without other etiology; early aggressive rhythm control recommended (Class I/B-NR)
• CASTLE-AF: Catheter ablation significantly reduced composite of death and HF hospitalization in HFrEF (HR 0.62)
• CABANA HF substudy: Ablation associated with 46% reduction in mortality in HF patients
• AF-CHF trial: Pharmacological rhythm control (primarily amiodarone) did not reduce cardiovascular mortality vs. rate control in HFrEF; however recent meta-analyses and ablation trials show benefit when ablation used

10. Early-Onset AF and Genetics (Section 10.1)

• AF <30 years: EP study reasonable to evaluate for reentrant SVTs (AVNRT, AVRT) — found in ~24–39% of young AF patients; targeted ablation resolves AF in majority (Class IIb/B-NR)
• AF <45 years, no obvious risk factors: Genetic counseling and testing for rare pathogenic variants (cardiomyopathy/channelopathy genes), surveillance for cardiomyopathy or arrhythmia syndromes is reasonable (Class IIb/B-NR) — 24% yield in selected series
• Consistent with EOAF-JAMA 2021 findings: ~10% of AF <66 carry P/LP variant; primarily cardiomyopathy genes

11. Special Populations (Section 10)

• Athletes: PVI is a reasonable first-line rhythm control strategy (Class IIa/B-NR); effective with low risk to exercise capacity; detraining not proven to reverse AF
• HCM: Reviewed but no substantive changes from 2020 HCM guideline; DOACs acceptable over warfarin; CHA₂DS₂-VASc not applicable — treat as score of 3
• AFL: OAC per same risk profile as AF (Class I/B-NR); OAC continued ≥4 weeks post-cardioversion or ablation; high-risk patients should receive monitoring post-CTI ablation given 16–82% AF incidence after flutter ablation
• Post-cardiac surgery AF: Prophylaxis with beta blockers or amiodarone (Class IIa/B-R); posterior left pericardiotomy (Class IIa/B-R); anticoagulate ≥60 days post-surgery if AF develops

Limitations of the document

• Most catheter ablation RCTs enrolled younger patients (avg. age ~60), limiting generalizability to older patients and those with significant comorbidities
• The 4-stage classification is novel and not yet validated prospectively
• CHA₂DS₂-VASc data underlying sex category retention were collected mostly from VKA-era trials; sex as an independent risk factor remains contested
• AHRE anticoagulation thresholds are based on ARTESiA and NOAH trials which gave discordant results — ARTESiA: apixaban reduced stroke but increased bleeding; NOAH: no net benefit with edoxaban
• Data supporting LRFM recommendations are largely observational or from secondary analyses
• Racial and ethnic diversity in ablation trial populations is limited; health disparities in AF care are acknowledged but not fully addressed
• No dedicated consideration of SGLT2 inhibitors for HF in AF (addressed more strongly in ESC 2024)

Key Concepts Mentioned

• concepts/AF-Staging — new 4-stage classification framework
• concepts/CHA2DS2-VA — ESC version; AHA retains CHA₂DS₂-VASc with sex
• concepts/Catheter-Ablation-AF — updated Class I recommendations
• concepts/AF-CARE — ESC framework; AHA uses LRFM + separate pillars

Key Entities Mentioned

• entities/Atrial-Fibrillation — comprehensive management update
• entities/Atrial-Flutter — detailed anticoagulation recommendations by CTI ablation status
• entities/HCM — OAC independent of CHA₂DS₂-VASc; DOACs acceptable
• entities/DCM — AF-induced cardiomyopathy; aggressive rhythm control

Wiki Pages Updated

• wiki/sources/AF-AHA-2023.md — created
• wiki/entities/Atrial-Fibrillation.md — updated (source_count 3→4; AHA content added)
• wiki/entities/Atrial-Flutter.md — updated (AHA AFL-specific anticoagulation detail)
• wiki/concepts/CHA2DS2-VA.md — updated (AHA CHA₂DS₂-VASc vs ESC CHA₂DS₂-VA contradiction)
• wiki/concepts/Catheter-Ablation-AF.md — updated (AHA Class I first-line data)
• wiki/concepts/AF-Staging.md — created (new 4-stage classification)
• wiki/index.md — updated
• wiki/log.md — updated